Global Health Solutions, INC S-1 registration statements

Turn Therapeutics, a biopharmaceutical company, reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing multiple drug and medical device candidates.

Turn Therapeutics, a biopharmaceutical company, plans a direct listing on Nasdaq for the resale of up to 17.87 million shares, despite significant net losses and a 'going concern' warning.

Turn Therapeutics, a biopharmaceutical company focused on dermatology and vaccine delivery, is preparing for a direct listing on Nasdaq, aiming to fund its advanced clinical trials and expand its proprietary PermaFusion technology.

Turn Therapeutics Inc., a pharmaceutical and medical device development company, files an S-1 registration statement for a direct listing on Nasdaq, focusing on its proprietary PermaFusion platform for dermatology and vaccine programs.